Patients who receive liver cancer treatments, including surgery and chemotherapy, experience several typical side effects. The side effects from surgery and chemotherapy differ according to the ...

You may also have signs of shock from blood loss. You normally won’t have any pain until your liver cancer has advanced to later stages. Once you do start to hurt, you may feel pain anywhere ...

A linear dose-dependent analysis showed that each daily consumption of 12 g of alcohol increased the risks for cirrhosis and hepatocellular carcinoma by 6.2% and 11.5%, respectively. HealthDay News — ...

January marks Love Your Liver month, prompting a doctor to raise awareness about liver cancer, a condition often detected at a late stage. As one of the most critical organs, the liver's health ...

AI decision support system non-homogenously influences clinical decisions in dynamic treatment regimen, as it depends on several factors including prior knowledge, preference, disease type ...

Current status of physicians’ perception of HCC conversion/downstaging therapy: A nationwide survey in China. A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination ...

A doctor has shared the four most common warning signs of liver cancer – a disease many people detect too late. January marks Love Your Liver awareness month, a time when we are encouraged to ...

Liver cancer is uncommon in the United States, but it is common worldwide due to risk factors such as chronic hepatitis B and C infections and exposure to aflatoxin (toxins produced by a certain ...

1Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. 2Department of Translational Medicine (DIMET), University of Piemonte ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...

Background and purpose: Microwave ablation (MWA) is one of the first-line therapy recommended for early-stage hepatocellular carcinoma (HCC). However, the residual tumor, resulting from insufficient ...

"To our knowledge, our study represents the first randomized, global study to report data for an anti-TIGIT monoclonal antibody in hepatocellular carcinoma," Finn and colleagues wrote in Lancet ...